Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of LY2157299 in Patients with Hepatocellular Carcinoma
2010-022338-10Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of galunisertib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Relationship of change in response biomarker to clinical benefit, Time-to-progression distributions and 1 more. Started Jan 2011; status: completed.
02
Drugs
galunisertib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2010-022338-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022338-10.